Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
Hypertrophic cardiomyopathy (HCM) thickens the left ventricle in your heart, which can make pumping blood harder and raise the risk of complications if untreated. HCM symptoms can be mild or absent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results